“Yeah, malpractice is a concern, but I’m really freaking out about hurting someone.” — Linda Isbell, PhD, of the University of Massachusetts Amherst, talking about her team’s survey that looked at perspectives of emergency clinicians on lawsuits and patient harm.
“I have not replaced Dr. [Leana] Wen because I did not want to leave any doubts that I was going to have her in the panel and I disagreed with the campaign that has been waged against her.” — Alfredo Morabia, MD, PhD, discussing the American Public Health Association annual meeting where public health expert Wen cancelled her scheduled appearance following threats made against her.
“It’s not ready for prime time, but it’s marvelous when these drugs come along.” — Jay Hoofnagle, MD, of the NIH in Bethesda, Maryland, commenting on a new hepatitis B drug showing promise in an early trial as a functional cure for some patients.
“Americans who are now in their 40s and 50s experienced more lead exposure as children than any other generation.” — John Robert Warren, PhD, of the University of Minnesota in Minneapolis, discussing lead exposure in childhood and cognitive function at older ages.
“In the space of rare diseases, everything begins with an N-of-1.” — Priya Kishnani, MD, of Duke University in Durham, North Carolina, on the first successful use of in utero enzyme replacement therapy in infantile-onset Pompe disease.
“It’s not just one thing. It’s environment, mindset. It’s training. It’s the patient population.” — Rolf T. Hansen III, PhD, of Teva Pharmaceuticals in New Jersey, on why long-acting injectables may be underutilized in schizophrenia.
“This is an extraordinary, groundbreaking study showing the effectiveness of a new drug for home acute treatment.” — Julia Indik, MD, PhD, of the University of Arizona College of Medicine in Tuscon, on an investigational self-administered nasal spray that shortened spontaneous paroxysmal supraventricular tachycardia episodes in patients at home.
“I don’t think we are arguing about the point estimates being impressive.” — FDA advisor Janet Lee, MD, of the University of Pittsburgh Medical Center, weighing whether evidence is sufficient to support the emergency use of novel agent sabizabulin in COVID-19.